Pharma BD Deal Intelligence

AbbVie Inc. / Mitokinin, Inc.

2023 · Acquisition/Merger · $655M · Complete

Announcement Sentiment

Strongly positive

AbbVie acquired Mitokinin, gaining its PINK1 mitochondrial kinase activator program for Parkinson's disease. Mitokinin shareholders received $110M upfront with up to $545M in additional milestone payments contingent on PINK1 program development.

Key facts

Announced Oct 09, 2023
Deal value $655M
Deal type Acquisition/Merger
Therapeutic area Parkinson's disease
Indications Parkinson's disease
Key assets PINK1 activator program — preclinical
Mechanism PINK1 (mitochondrial kinase) activator

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals